Pharmacy Law, Ethics and Regulatory Affairs
Regulatory architecture
Know the approval pathways: a full New Drug Application with clinical evidence, an ANDA for generic equivalence (same active ingredient, strength, dosage form, route, quality and bioequivalence), and a 505(b)(2) pathway relying partly on existing literature. Over-the-counter products may follow a monograph system. Post-marketing obligations include adverse-event reporting, pharmacovigilance signals, REMS for serious-risk drugs, and product traceability requirements.
Controlled substances
Schedules are ranked by abuse potential and accepted medical use, with Schedule I having no accepted medical use; the exact scheduling and refill rules are jurisdiction-specific, so answer according to the framework your exam states - commonly: Schedule II prescriptions require written or specially authorised electronic issuance with no refills, while lower schedules permit a limited number of refills within a defined period. Always verify prescriber authority, patient identity, and quantity limits.
Ethics and consent
Four principles anchor ethical questions: beneficence, non-maleficence, autonomy (informed consent, confidentiality) and justice (fair allocation). Conflicts of interest, gifts from industry, patient privacy, and duty to report errors are frequent scenarios. Follow the patient's best interest, disclose conflicts, and document decisions.
Traps
- Confusing dispensing error (wrong drug supplied) with prescribing error (wrong drug chosen).
- Forgetting that generic substitution requires therapeutic equivalence, not just the same name.
- Missing jurisdiction: local health-authority licensing, controlled-drug registers and record-retention rules may differ from the exam's reference country - read the stem carefully.
Rule of thumb
When a legal and an ethical duty appear to conflict, protect patient safety first, act within your scope of practice, and escalate through documented channels.